Part:BBa_K3661002

YebF-IL 22

This composite part is composed of the secretion part of YebF and the part of anti-inflammatory factor IL-22.The IL-22 is a natural immunosuppressive protein. We add a secretion tag to increase the extracellular concentration. YebF secretion system is widely used in E.coli.IL-22 can be secreted from our engineered bacteria through this system efficiently. Interleukin-22(IL-22) is a member of a group of the IL-10 family, a class of potent mediators of cellular inflammatory responses. IL-22 is produced by activated DC and T cells. IL-22 and IL-10 receptor chains play a role in cellular targeting and signal transduction. It can initiate and regulate innate immune responses against bacterial pathogens especially in epithelial cells such as respiratory and gut epithelial cells.

Usage

Figure 1.Diagram for human IL-22 expressing and secreting in pET-28a(+) plasmid.

Interleukin-22(IL-22) is a cytokine that inhibits inflammation.

The secretory tag YebF increases extracellular concentrations of IL-22.

T7 promoter, the gene downstream of this promoter will be transcribed when there is T7 RNA polymerase. RBS, ribosome biding site. Terminator blocks gene sequence reads.

Figure 2.Full sequence mapping of pET-28a(+) plasmid.

The plasmid carries the kanamycin resistance gene.

Biology

YebF proteins are widely found in E.coliEnterobacteriaceae bacteria, and are soluble endogenous short peptides that can be secreted into the extracellular medium. When other proteins are fused to the YebF sequence, YebF can help secrete these proteins out of the E. coli membrane.[1]

IL-22 is a member of the IL-10 family and is primarily a cytokine secreted by Th22 cells [2].

Interleukin 22 reduces inflammation through the JAK-STAT pathway as well as the NF-κB pathway to inhibit TNF-α production, reducing hepatocyte apoptosis and protecting hepatocytes [3].

Characterization

We constructed a plasmid containing YebF-IL22. Meanwhile, We constructed a secretory expression vector for IL-22, using Escherichia coli as chasis. IL-22 was detected using an ELISA kit.

Figure 3.Result of activity assay using human IL-22 ELISA kit.

(A1/B1) are blank-corrected wells. Wells (A2/B2), (A3/B3), (A4/B4), (A5/B5), (A6/B6), (A7/B7), (A8/B8) are standard human IL-22 protein sample with concentration at 2000pg/ml, 1000pg/ml, 500pg/ml, 250pg/ml, 150pg/ml, 62.5pg/ml and 0pg/ml respectively. Wells C1-C3 are duplicate wells for protein sample 1 while C4-C6 are duplicate wells for protein sample 2. C7-C8 are negative control wells. Protein sample 1 was induced by adding 1M of IPTG, and protein sample 2 was induced by adding 0.5M. No induction agent was added to the negative control group.

Figure 4.Standard curve of human IL-22.

Table 1

Table 2

Table 1&2 Result of activity assay using human IL-22 ELISA kit.

The protein expression of protein sample 1 is approximately 5.43ng/ml, while sample 2 is approximately 3.094ng/ml.

Figure 5Comparison of Corrected A450 of Sample Groups.

Both sample groups were significantly different compared to the negative control group.*P < 0.05, ** P < 0.01, *** P < 0.001, and ****P < 0.0001 by t test.

Reference

[1]ZHANG G,BROKX S,WEINER J H. Extracellular accumulation of recombinant proteins fused to the carrier protein YebF in Escherichia coli [J]. Nature Biotechnology.2006.24(1)：100-104.

[2] Shabgah A G , Navashenaq J G , Shabgah G , et al. Interleukin-22 in human inflammatory diseases and viral infections.[J]. Autoimmunity Reviews, 2017: S1568997217302549.

[3] Radaeva S, Sun R, Pan HN, Hong F, Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation [J]. Hepatology, 2004; 39: 1332-1342.

Sequence and Features

Assembly Compatibility:

• 10
  COMPATIBLE WITH RFC[10]
• 12
  INCOMPATIBLE WITH RFC[12]

  Illegal NheI site found at 547
  
• 21
  INCOMPATIBLE WITH RFC[21]

  Illegal BglII site found at 108
  
• 23
  COMPATIBLE WITH RFC[23]
• 25
  COMPATIBLE WITH RFC[25]
• 1000
  COMPATIBLE WITH RFC[1000]